Novartis Ag (NVS) Times Interest Earned (2009 - 2025)
Novartis Ag recorded quarterly Times Interest Earned of -$16.83 in Q2 2025, up 37.34% quarter-over-quarter from -$26.86 in Q4 2024, and down 3.15% year-over-year from -$17.38 in Q2 2024.
Novartis Ag's Times Interest Earned history runs 16 years deep, the most recent figure standing at -$16.83 for Q2 2025.
- In Q2 2025, Times Interest Earned fell 3.15% year-over-year to -$16.83; the TTM figure through Jun 2025 stood at -$19.75 (down 15.21% YoY), while the FY2025 annual figure was $15.42, up 6.68% from the prior year.
- Times Interest Earned came in at -$16.83 for Q2 2025 at Novartis Ag, up from -$26.86 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of -$1.32 in Q4 2022 to a low of -$26.86 in Q4 2024.
- A 5-year average of -$10.68 and a median of -$6.9 in 2021 frame the typical range for Times Interest Earned.
- Across the five-year window, Times Interest Earned tumbled 1795.6% in 2023 and jumped 38.98% in 2024, its largest moves.
- Novartis Ag's Times Interest Earned stood at -$1.87 in 2021, then gained by 29.62% to -$1.32 in 2022, then sank by 1795.6% to -$25.0 in 2023, then fell by 7.45% to -$26.86 in 2024, then surged by 37.34% to -$16.83 in 2025.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$16.83, -$26.86, and -$16.32 for Q2 2025, Q4 2024, and Q2 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 23.39 |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | - |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | - |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 4.06 |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 10.78 |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | - |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -16.83 |
| Dec 31, 2024 | -26.86 |
| Jun 30, 2024 | -16.32 |
| Dec 31, 2023 | -25.00 |
| Jun 30, 2023 | -26.74 |
| Mar 31, 2023 | -1.60 |
| Dec 31, 2022 | -1.32 |
| Sep 30, 2022 | -1.83 |
| Jun 30, 2022 | -11.63 |
| Mar 31, 2022 | -1.96 |
| Dec 31, 2021 | -1.87 |
| Sep 30, 2021 | -2.18 |
| Jun 30, 2021 | -13.85 |
| Mar 31, 2021 | -1.54 |
| Dec 31, 2020 | -1.85 |
| Sep 30, 2020 | -1.89 |
| Jun 30, 2020 | -11.20 |
| Mar 31, 2020 | 0.19 |
| Mar 31, 2019 | -1.21 |
| Dec 31, 2018 | -0.96 |
| Sep 30, 2018 | -1.56 |
| Jun 30, 2018 | -10.48 |
| Mar 31, 2018 | -1.88 |
| Dec 31, 2017 | -1.47 |
| Sep 30, 2017 | -1.98 |
| Jun 30, 2017 | -11.88 |
| Mar 31, 2017 | -1.91 |
| Dec 31, 2016 | -44.85 |
| Sep 30, 2016 | -2.03 |
| Jun 30, 2016 | -2.11 |
| Mar 31, 2016 | 0.00 |
| Dec 31, 2015 | -1.37 |
| Mar 31, 2015 | -1.90 |
| Dec 31, 2014 | -1.94 |
| Sep 30, 2014 | -2.09 |
| Mar 31, 2014 | -4.01 |
| Sep 30, 2012 | -2.02 |
| Jun 30, 2012 | -2.29 |
| Mar 31, 2012 | -2.21 |
| Dec 31, 2011 | -4.74 |
| Sep 30, 2011 | -1.72 |
| Jun 30, 2011 | -1.95 |
| Mar 31, 2011 | -2.77 |
| Dec 31, 2010 | -1.57 |
| Sep 30, 2010 | -2.29 |
| Jun 30, 2010 | -1.68 |
| Mar 31, 2010 | -26.40 |
| Dec 31, 2009 | 0.00 |
| Sep 30, 2009 | -15.23 |
| Jun 30, 2009 | -1.99 |
| Mar 31, 2009 | -27.29 |